- Collaboration seeks to advance precision care by providing an
alternative, non-invasive approach to the assessment of coronary
physiology.
- Both companies will focus on the integration of Medis QFR into
GE HealthCare’s cath lab environment built around the Allia
Platform to enable a seamless user experience.
Today, GE HealthCare (Nasdaq: GEHC), a leading global medical
technology, pharmaceutical diagnostics and digital solutions
innovator, and Medis Medical Imaging, a leading cardiac imaging
software company, announced their collaboration aimed at helping
advance precision care in the diagnosis and treatment of coronary
artery disease (CAD). Together, the two companies will work to
further the development and commercialization of Medis Quantitative
Flow Ratio (Medis QFR), a non-invasive approach to the assessment
of coronary physiology, as part of GE HealthCare’s interventional
cardiology portfolio built around the Allia Platform. The
collaboration seeks to provide access to emerging technologies,
like Medis QFR, while also reducing complexity in the cath lab to
improve the operating environment for clinicians.
Within the complex umbrella of cardiovascular disease, CAD is a
type of heart disease that develops when the coronary arteries
narrow and the heart cannot deliver enough oxygen-rich blood to the
heart. The impact of this narrowing can ultimately result in angina
(chest pain), which has been shown to double the risk of major
cardiovascular events,1 as well as myocardial infarction (heart
attack) or even death. In order to accurately diagnose suspected
CAD, a significant percentage of patients can undergo invasive
coronary angiography to help clinicians determine the severity of
their disease. Traditionally, a clinician will then visually
interpret an angiogram to determine whether a patient requires
treatment, such as a percutaneous coronary intervention (PCI), as
well as determine where, or which lesion, to treat to restore blood
flow.
As part of GE HealthCare’s commitment to advancing precision
care in interventional cardiology, the company’s collaboration with
Medis Medical Imaging will bring Medis QFR to clinicians as an
emerging, non-invasive, image-based diagnostic approach to the
assessment of coronary artery physiology and the treatment of CAD.
The benefits of QFR guidance are supported in a recent study that
showed that a QFR-guided strategy of lesion selection for PCI
improved two-year clinical outcomes, including reduction in
myocardial infraction and ischemia-driven revascularization, when
compared with standard angiography guidance alone.2
“We continue to see an evolution in how clinicians work to treat
cardiovascular disease and want to give clinicians the tools, along
with the flexibility and adaptability, they need to enable better
outcomes for their patients,” says Arnaud Marie – General Manager
for Global Intervention at GE HealthCare. “In the assessment of
coronary artery disease, QFR represents a significant advancement
in how efficiently it can provide critical insights. We’re excited
to collaborate with Medis Medical Imaging to add innovative,
non-invasive, image-based QFR to our portfolio of offerings around
our Allia IGS platform to streamline the experience for clinicians
and help us to deliver on our vision for the future image-guided
therapy.”
Medis Medical Imaging has been developing innovative
post-processing software for the quantification of cardiovascular
images for thirty-five years. Medis’ QFR is a proprietary solution
that delivers image-based physiology of coronary obstructions based
on angiography imaging analysis alone. Interventional cardiologists
can seamlessly adopt the solution into their clinical workflow to
help them effectively and efficiently determine if a PCI is
required to treat the patient or if treatment should be deferred
for ongoing monitoring or other alternative treatment options. If
treatment is needed, Medis’ QFR technology can help clinicians
select the ultimate lesion(s) for treatment and create the right
treatment plan for a balloon or stent-based PCI procedure, while
also helping the clinician evaluate the efficacy of that treatment.
This analysis can be performed in real time while the patient is on
the table and results are displayed on the large display monitor in
the cath lab.
“We are absolutely delighted to be taking this next step with GE
HealthCare, a fellow leader in the interventional cardiology
domain,” shares Maya Barley, CEO Medis Medical Imaging. “Building
on Medis QFR’s decade of AI research, customer-focused product
development, clinical evidence generation and business development,
we are excited to be able to further accelerate our efforts around
Medis QFR to enable more hospitals and clinicians to apply
physiology in day-to-day interventional practice a part of
best-practice clinical care – making this technology more
accessible and available to patients than ever before.”
Innovative technologies like Medis QFR enhance GE HealthCare’s
comprehensive portfolio of interventional cardiology solutions
built around the Allia Platform designed to optimize workflows,
unlock efficiencies, and drive better patient outcomes in the
treatment of cardiovascular disease.
To learn more about GE HealthCare’s latest innovations in
interventional cardiology including Allia IGS Pulse, the next
generation of image-guided systems for cardiac imaging, or Medis
QFR, please visit the EuroPCR 2024 congress booth #F15 in Paris,
France from May 14 – 17 or visit the website here.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology,
pharmaceutical diagnostics, and digital solutions innovator,
dedicated to providing integrated solutions, services, and data
analytics to make hospitals more efficient, clinicians more
effective, therapies more precise, and patients healthier and
happier. Serving patients and providers for more than 125 years, GE
HealthCare is advancing personalized, connected, and compassionate
care, while simplifying the patient’s journey across the care
pathway. Together our Imaging, Ultrasound, Patient Care Solutions,
and Pharmaceutical Diagnostics businesses help improve patient care
from diagnosis, to therapy, to monitoring. We are a $19.6 billion
business with approximately 51,000 colleagues working to create a
world where healthcare has no limits.
Follow us on LinkedIn, X (formerly Twitter), and Insights for
the latest news, or visit our website https://www.gehealthcare.com/
for more information.
About Medis Medical Imaging
For over 35 years, Medis has been providing high-quality
quantitative analysis solutions for cardiovascular imaging to the
medical community. Our heritage and core values are based on this
strong purpose of contributing to a healthier society by providing
the right tools to clinicians worldwide. Medis’ software is
internationally appreciated due to its ease of use and its clinical
outcome for the patients. At Medis, quality is key, all our
products are developed and validated extensively to guarantee the
highest quality, without compromise. We continuously focus on the
creation of clinically relevant innovative software solutions in
the cardiovascular imaging domain.
1 World Health Federation. Use Heart to Act on Angina. Available
at:
https://world-heart-federation.org/use-heart-to-act-now-on-angina/.
Accessed May 2024.
2 Lei Song, Bo Xu, Shengxian Tu, Changdong Guan, Zening Jin, Bo
Yu, Guosheng Fu, Yujie Zhou, Jian’an Wang, Yundai Chen, Jun Pu,
Lianglong Chen, Xinkai Qu, Junqing Yang, Xuebo Liu, Lijun Guo,
Chengxing Shen, Yaojun Zhang, Qi Zhang, Hongwei Pan, Rui Zhang,
Jian Liu, Yanyan Zhao, Yang Wang, Kefei Dou, Ajay J. Kirtane,
Yongjian Wu, William Wijns, Weixian Yang, Martin B. Leon, Shubin
Qiao, Gregg W. Stone, 2-Year Outcomes of Angiographic Quantitative
Flow Ratio-Guided Coronary Interventions, Journal of the American
College of Cardiology, Volume 80, Issue 22, 2022, Pages 2089-2101,
ISSN 0735-1097, https://doi.org/10.1016/j.jacc.2022.09.007.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240514519396/en/
GE HealthCare Karin Dalsin Global Communications Director
karin.dalsin@gehealthcare.com +1-612-219-2855
Medis Medical Imaging Arnoud van Dorth Head of Marketing
avandorth@medisimaging.com +31 655697535
GE HealthCare Technologies (NASDAQ:GEHC)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
GE HealthCare Technologies (NASDAQ:GEHC)
Gráfica de Acción Histórica
De May 2023 a May 2024